Patient Perspective: A conversation with Philip Yeske, PhD – Science & Alliance Officer, UMDF

find more articles

Khondrion and Medvisis Announce Exclusive Licensing Agreement to Commercialize Sonlicromanol for Primary Mitochondrial Diseases in Switzerland and Liechtenstein

Khondrion Secures EU Orphan Drug Designation for Lead Compound Sonlicromanol in Treatment of Inherited Mitochondrial Oxidative Phosphorylation Defects

Clarifying the Phenotypic Spectrum of m.3243A>G: A Proposal for Terminological Precision in PMD

view all articles